Author + information
- Shengjie Lu1,
- Jaryl Ng1,
- Hui Ying Ang1,
- Valeria Paradies2,
- Philip Wong3,
- Rasha Al-Lamee4,
- Kadem Al-Lamee5,
- Nial Bullett6,
- Naveed Ahmed6,
- Michael Joner7 and
- Nicolas Foin1
- 1National Heart Centre Singapore, Singapore, Singapore
- 2National Heart Research Institute and National Heart Centre Singapore, Singapore, Singapore
- 3National Heart Center Singapore, Duke NUS Medical School, Singapore, Singapore
- 4Imperial College London, London, United Kingdom
- 5ARTERIUS Limited, Leeds, United Kingdom
- 6Arterius, Leeds, United Kingdom
- 7Deutsches Herzzentrum München, Munich, Germany
Late stent thrombosis is one of the major complication of percutaneous coronary intervention. It has been suggested that strut thickness of currently available bioresorbable vascular scaffolds (BRS) may impact on thrombogenicity.
In this study we assessed the thrombus formation of everolimus-eluting Xience stent (81μm), with BVS (157μm) and thin-strut bioresorbable scaffolds (ArterioSorb BRS, 95μm) (3.0mm size, n=3 per group) deployed in an in-vitro coronary model. The samples were perfused with porcine blood at a rate of 200m/min for 4 minutes. Mean thrombus area was evaluated using optical coherence tomography (OCT) and immunofluorescence (IF) and mean fluorescent intensity measured at confocal microscopy.
At IF analysis, thin-strut BRS showed a significantly smaller thrombus area as compared to BVS (0.006vs0.035 mm2/mm, p<0.01). No difference was found in terms of thrombus area between thin-strut BRS and Xience (0.006vs0.007 mm2/mm, p=0.98). A similar trend was observed in mean fluorescent intensity and OCT cross-sectional thrombus area. (Fig 1)
In-vitro perfusion models suggest that strut thickness may impact on BRS thrombogenicity.
CORONARY: Bioresorbable Vascular Scaffolds